{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T01:39:07Z","timestamp":1792719547754,"version":"4.5.0"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T00:00:00Z","timestamp":1784937600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T00:00:00Z","timestamp":1792713600000},"content-version":"vor","delay-in-days":90,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Pharm Health Care Sci"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      Depression is a serious mental disorder that impairs both psychological and physical functioning. When depression occurs in individuals in their 20s and 30s, it may adversely affect not only the continuation of academic or occupational activities but also interpersonal relationships in educational and workplace settings. Therefore, appropriate pharmacotherapy is essential for this patient population. Although several studies have evaluated newer antidepressants in recent years, detailed information regarding adverse effects in routine clinical practice remains limited, and studies focusing specifically on younger populations are scarce. The aim of this study was to compare the incidence and characteristics of adverse events associated with two newer antidepressants frequently prescribed to young patients in clinical practice, escitalopram (Lexapro\n                      <jats:sup>\u00ae<\/jats:sup>\n                      ) and vortioxetine (Trintellix\n                      <jats:sup>\u00ae<\/jats:sup>\n                      ), and to explore strategies for ensuring safe pharmacotherapy.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      This retrospective study analyzed patients with depression who were prescribed escitalopram or vortioxetine between 2019 and 2024. Clinical data were collected from medical records, with a follow-up period of 3 months. Statistical analysis was performed using EZR, with a significance level set at\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.05.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The incidence of adverse events was significantly higher in the vortioxetine group than in the escitalopram group. Among the observed adverse events, nausea occurred significantly more frequently in patients receiving vortioxetine. Furthermore, a lower incidence of nausea was observed among patients who received concomitant gastrointestinal medications.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The findings of this study suggest that concomitant gastrointestinal medication use may be associated with a lower incidence of nausea among young patients treated with vortioxetine. Although causal relationships cannot be established because of the retrospective study design, these findings may provide preliminary real-world evidence regarding the management of vortioxetine-associated nausea. Further prospective studies are needed to confirm these observations.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s40780-026-00613-y","type":"journal-article","created":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T07:34:23Z","timestamp":1784964863000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Adverse effects of escitalopram and vortioxetine in young patients with depression: a retrospective comparative study"],"prefix":"10.1186","volume":"12","author":[{"given":"Ayae","family":"Nomura","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuki","family":"Takayama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayane","family":"Miyazawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuuma","family":"Higashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroaki","family":"Yoshinari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoki","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinya","family":"Takasaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,25]]},"reference":[{"key":"613_CR1","doi-asserted-by":"publisher","first-page":"e56960","DOI":"10.2196\/56960","volume":"13","author":"B Rothman","year":"2024","unstructured":"Rothman B, Slomkowski M, Speier A, Rush AJ, Trivedi MH, Lawson E, et al. Evaluating the Efficacy of a Digital Therapeutic (CT-152) as an Adjunct to Antidepressant Treatment in Adults With Major Depressive Disorder: Protocol for the MIRAI Remote Study. JMIR Res Protoc. 2024;13:e56960. https:\/\/doi.org\/10.2196\/56960.","journal-title":"JMIR Res Protoc"},{"key":"613_CR2","doi-asserted-by":"publisher","first-page":"102521","DOI":"10.1016\/j.cpr.2024.102521","volume":"115","author":"RL Dean","year":"2025","unstructured":"Dean RL, Lester KJ, Grant E, Field AP, Orchard F, Pile V. The impact of interventions for depression on self-perceptions in young people: A systematic review & meta-analysis. Clin Psychol Rev. 2025;115:102521. https:\/\/doi.org\/10.1016\/j.cpr.2024.102521.","journal-title":"Clin Psychol Rev"},{"issue":"5","key":"613_CR3","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1016\/j.jaac.2022.10.001","volume":"62","author":"HJ Walter","year":"2023","unstructured":"Walter HJ, Abright AR, Bukstein OG, Diamond J, Keable H, Ripperger-Suhler J, et al. Clinical Practice Guideline for the Assessment and Treatment of Children and Adolescents With Major and Persistent Depressive Disorders. J Am Acad Child Adolesc Psychiatry. 2023;62(5):479\u2013502. https:\/\/doi.org\/10.1016\/j.jaac.2022.10.001.","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"issue":"1","key":"613_CR4","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1186\/s12888-023-05382-8","volume":"23","author":"J Yin","year":"2023","unstructured":"Yin J, Song X, Wang C, Lin X, Miao M. Escitalopram versus other antidepressive agents for major depressive disorder: a systematic review and meta-analysis. BMC Psychiatry. 2023;23(1):876. https:\/\/doi.org\/10.1186\/s12888-023-05382-8.","journal-title":"BMC Psychiatry"},{"key":"613_CR5","doi-asserted-by":"publisher","first-page":"853","DOI":"10.2147\/ppa.S22495","volume":"6","author":"E Kirino","year":"2012","unstructured":"Kirino E. Escitalopram for the management of major depressive disorder: a review of its efficacy, safety, and patient acceptability. Patient Prefer Adherence. 2012;6:853\u201361. https:\/\/doi.org\/10.2147\/ppa.S22495.","journal-title":"Patient Prefer Adherence"},{"key":"613_CR6","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.pharmthera.2014.07.001","volume":"145","author":"C Sanchez","year":"2015","unstructured":"Sanchez C, Asin KE, Artigas F. Vortioxetine, a novel antidepressant with multimodal activity: review of preclinical and clinical data. Pharmacol Ther. 2015;145:43\u201357. https:\/\/doi.org\/10.1016\/j.pharmthera.2014.07.001.","journal-title":"Pharmacol Ther"},{"issue":"6","key":"613_CR7","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1007\/s40262-017-0612-7","volume":"57","author":"G Chen","year":"2018","unstructured":"Chen G, H\u00f8jer AM, Areberg J, Nomikos G, Vortioxetine. Clinical Pharmacokinetics and Drug Interactions. Clin Pharmacokinet. 2018;57(6):673\u201386. https:\/\/doi.org\/10.1007\/s40262-017-0612-7.","journal-title":"Clin Pharmacokinet"},{"issue":"6","key":"613_CR8","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1093\/ijnp\/pyad018","volume":"26","author":"Z Li","year":"2023","unstructured":"Li Z, Liu S, Wu Q, Li J, Yang Q, Wang X, et al. Effectiveness and Safety of Vortioxetine for the Treatment of Major Depressive Disorder in the Real World: A Systematic Review and Meta-Analysis. Int J Neuropsychopharmacol. 2023;26(6):373\u201384. https:\/\/doi.org\/10.1093\/ijnp\/pyad018.","journal-title":"Int J Neuropsychopharmacol"},{"issue":"3","key":"613_CR9","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1111\/j.1527-3458.2001.tb00198.x","volume":"7","author":"SA Anttila","year":"2001","unstructured":"Anttila SA, Leinonen EV. A review of the pharmacological and clinical profile of mirtazapine. CNS Drug Rev. 2001;7(3):249\u201364. https:\/\/doi.org\/10.1111\/j.1527-3458.2001.tb00198.x.","journal-title":"CNS Drug Rev"},{"issue":"7","key":"613_CR10","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1002\/phar.2767","volume":"43","author":"JR Strawn","year":"2023","unstructured":"Strawn JR, Mills JA, Poweleit EA, Ramsey LB, Croarkin PE. Adverse Effects of Antidepressant Medications and their Management in Children and Adolescents. Pharmacotherapy. 2023;43(7):675\u201390. https:\/\/doi.org\/10.1002\/phar.2767.","journal-title":"Pharmacotherapy"},{"issue":"9","key":"613_CR11","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1016\/s2215-0366(21)00154-1","volume":"8","author":"SE Murphy","year":"2021","unstructured":"Murphy SE, Capit\u00e3o LP, Giles SLC, Cowen PJ, Stringaris A, Harmer CJ. The knowns and unknowns of SSRI treatment in young people with depression and anxiety: efficacy, predictors, and mechanisms of action. Lancet Psychiatry. 2021;8(9):824\u201335. https:\/\/doi.org\/10.1016\/s2215-0366(21)00154-1.","journal-title":"Lancet Psychiatry"},{"issue":"5","key":"613_CR12","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1001\/jamapsychiatry.2020.3285","volume":"78","author":"AK Davis","year":"2021","unstructured":"Davis AK, Barrett FS, May DG, Cosimano MP, Sepeda ND, Johnson MW, et al. Effects of Psilocybin-Assisted Therapy on Major Depressive Disorder: A Randomized Clinical Trial. JAMA Psychiatry. 2021;78(5):481\u20139. https:\/\/doi.org\/10.1001\/jamapsychiatry.2020.3285.","journal-title":"JAMA Psychiatry"},{"issue":"3","key":"613_CR13","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1016\/s0165-1781(01)00320-1","volume":"104","author":"N Ueda","year":"2001","unstructured":"Ueda N, Yoshimura R, Shinkai K, Terao T, Nakamura J. Characteristics of fluvoxamine-induced nausea. Psychiatry Res. 2001;104(3):259\u201364. https:\/\/doi.org\/10.1016\/s0165-1781(01)00320-1.","journal-title":"Psychiatry Res"},{"issue":"1","key":"613_CR14","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1186\/s12199-021-00953-1","volume":"26","author":"K Nomura","year":"2021","unstructured":"Nomura K, Minamizono S, Maeda E, Kim R, Iwata T, Hirayama J, et al. Cross-sectional survey of depressive symptoms and suicide-related ideation at a Japanese national university during the COVID-19 stay-home order. Environ Health Prev Med. 2021;26(1):30. https:\/\/doi.org\/10.1186\/s12199-021-00953-1.","journal-title":"Environ Health Prev Med"},{"issue":"3","key":"613_CR15","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1038\/bmt.2012.244","volume":"48","author":"Y Kanda","year":"2013","unstructured":"Kanda Y. Investigation of the freely available easy-to-use software \u2018EZR\u2019 for medical statistics. Bone Marrow Transpl. 2013;48(3):452\u20138. https:\/\/doi.org\/10.1038\/bmt.2012.244.","journal-title":"Bone Marrow Transpl"},{"issue":"1","key":"613_CR16","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1038\/s41380-022-01824-z","volume":"28","author":"T Kishi","year":"2023","unstructured":"Kishi T, Ikuta T, Sakuma K, Okuya M, Hatano M, Matsuda Y, et al. Antidepressants for the treatment of adults with major depressive disorder in the maintenance phase: a systematic review and network meta-analysis. Mol Psychiatry. 2023;28(1):402\u20139. https:\/\/doi.org\/10.1038\/s41380-022-01824-z.","journal-title":"Mol Psychiatry"},{"key":"613_CR17","unstructured":"Administration USFaD. LEXAPRO (escitalopram oxalate) tablets prescribing information 2023 [updated 2023. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/021323s055,021365s039lbl.pdf"},{"key":"613_CR18","unstructured":"Administration USFaD. Trintellix (vortioxetine) tablets prescribing information 2023 2023. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/204447s026lbl.pdf."},{"issue":"2","key":"613_CR19","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1111\/pcn.12623","volume":"72","author":"T Inoue","year":"2018","unstructured":"Inoue T, Nishimura A, Sasai K, Kitagawa T, Randomized. 8-week, double-blind, placebo-controlled trial of vortioxetine in Japanese adults with major depressive disorder, followed by a 52-week open-label extension trial. Psychiatry Clin Neurosci. 2018;72(2):103\u201315. https:\/\/doi.org\/10.1111\/pcn.12623.","journal-title":"Psychiatry Clin Neurosci"},{"issue":"9","key":"613_CR20","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1177\/0706743716659417","volume":"61","author":"SH Kennedy","year":"2016","unstructured":"Kennedy SH, Lam RW, McIntyre RS, Tourjman SV, Bhat V, Blier P, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 Clinical Guidelines for the Management of Adults with Major Depressive Disorder: Sect.\u00a0 3. Pharmacological Treatments. Can J Psychiatry. 2016;61(9):540\u201360. https:\/\/doi.org\/10.1177\/0706743716659417.","journal-title":"Can J Psychiatry"},{"key":"613_CR21","doi-asserted-by":"publisher","first-page":"110266","DOI":"10.1016\/j.pnpbp.2021.110266","volume":"109","author":"V Oliva","year":"2021","unstructured":"Oliva V, Lippi M, Paci R, Del Fabro L, Delvecchio G, Brambilla P, et al. Gastrointestinal side effects associated with antidepressant treatments in patients with major depressive disorder: A systematic review and meta-analysis. Prog Neuropsychopharmacol Biol Psychiatry. 2021;109:110266. https:\/\/doi.org\/10.1016\/j.pnpbp.2021.110266.","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"613_CR22","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/j.jad.2018.09.015","volume":"243","author":"F Rice","year":"2019","unstructured":"Rice F, Riglin L, Lomax T, Souter E, Potter R, Smith DJ, et al. Adolescent and adult differences in major depression symptom profiles. J Affect Disord. 2019;243:175\u201381. https:\/\/doi.org\/10.1016\/j.jad.2018.09.015.","journal-title":"J Affect Disord"},{"issue":"7","key":"613_CR23","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1016\/s2215-0366(20)30137-1","volume":"7","author":"X Zhou","year":"2020","unstructured":"Zhou X, Teng T, Zhang Y, Del Giovane C, Furukawa TA, Weisz JR, et al. Comparative efficacy and acceptability of antidepressants, psychotherapies, and their combination for acute treatment of children and adolescents with depressive disorder: a systematic review and network meta-analysis. Lancet Psychiatry. 2020;7(7):581\u2013601. https:\/\/doi.org\/10.1016\/s2215-0366(20)30137-1.","journal-title":"Lancet Psychiatry"},{"issue":"9","key":"613_CR24","doi-asserted-by":"publisher","first-page":"1637","DOI":"10.1080\/03007995.2024.2382773","volume":"40","author":"M Adair","year":"2024","unstructured":"Adair M, Bose R, Schmidt SN. Safety and effectiveness of vortioxetine in patients with major depressive disorder in a real-life clinical setting in India: results from an interventional, flexible-dose study. Curr Med Res Opin. 2024;40(9):1637\u201345. https:\/\/doi.org\/10.1080\/03007995.2024.2382773.","journal-title":"Curr Med Res Opin"},{"issue":"5","key":"613_CR25","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1080\/03007995.2022.2031146","volume":"38","author":"R Bose","year":"2022","unstructured":"Bose R, Hamdani SU, Minhas FA, Herr KJ. A comparison of real-world effectiveness of vortioxetine along the treatment algorithm for major depressive disorder. Curr Med Res Opin. 2022;38(5):661\u201371. https:\/\/doi.org\/10.1080\/03007995.2022.2031146.","journal-title":"Curr Med Res Opin"},{"issue":"1","key":"613_CR26","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1254\/jphs.12175fp","volume":"121","author":"Y Mine","year":"2013","unstructured":"Mine Y, Oku S, Yoshida N. Anti-emetic effect of mosapride citrate hydrate, a 5-HT4 receptor agonist, on selective serotonin reuptake inhibitors (SSRIs)-induced emesis in experimental animals. J Pharmacol Sci. 2013;121(1):58\u201366. https:\/\/doi.org\/10.1254\/jphs.12175fp.","journal-title":"J Pharmacol Sci"},{"key":"613_CR27","doi-asserted-by":"publisher","unstructured":"Krishna V, Bairy KL, Patil N, Sunny SV. Evaluation of the antianxiety and antidepressant activities of mosapride in Wistar Albino rats. J Basic Clin Physiol Pharmacol. 2019;30(4). https:\/\/doi.org\/10.1515\/jbcpp-2018-0089.","DOI":"10.1515\/jbcpp-2018-0089"}],"container-title":["Journal of Pharmaceutical Health Care and Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40780-026-00613-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40780-026-00613-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40780-026-00613-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T01:21:41Z","timestamp":1792718501000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40780-026-00613-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,25]]},"references-count":27,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["613"],"URL":"https:\/\/doi.org\/10.1186\/s40780-026-00613-y","relation":{},"ISSN":["2055-0294"],"issn-type":[{"value":"2055-0294","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,25]]},"assertion":[{"value":"3 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was approved by the Ethics Review Committee of the International University of Health and Welfare (approval number: 24-Io-12-2) and was conducted in accordance with the ethical principles of the Declaration of Helsinki. Participants were informed of the study through an approved opt-out procedure and were given the opportunity to decline participation.","order":1,"name":"Ethics","label":"Ethics declarations","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"91"}}